SCHEMBL5657726

SCHEMBL5657726

NC(=O)N1CCC(C2CCN(C(=O)[CH]Cc3cc(C(F)(F)F)c4[nH]ncc4c3)CC2)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
CALCA P06881 2/20 0.35
PTGES O14684 2/20 0.34
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
PAK1 Q13153 2/20 0.33
TRPV1 Q8NER1 2/20 0.32
CHRM5 P08912 5/20 0.32
F2 P00734 1/20 0.32
F10 P00742 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
PREP P48147 1/20 0.31
ROCK2 O75116 1/20 0.30
CYP3A4 P08684 1/20 0.30
BTK Q06187 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5660550 0.91 CALCA (0.40) RXRARXRBRXRGCALCAACACB
SCHEMBL5659967 0.91 CALCA (0.40) RXRARXRBRXRGCALCAACACB
SCHEMBL5658453 0.85 CALCA (0.33) CALCAPAK1ROCK2CYP3A4BTK
SCHEMBL5660254 0.85 CYP3A4 (0.36) CALCAPAK1ROCK2CYP3A4BTK
SCHEMBL5659680 0.85 CYP3A4 (0.37) CALCAACACBROCK2CYP3A4BTK
SCHEMBL5660671 0.79 ROCK2 (0.44) ROCK2CYP3A4
SCHEMBL5658727 0.78 BTK (0.36) F2F10ROCK2CYP3A4BTK
SCHEMBL5659437 0.78 BTK (0.36) ROCK2CYP3A4BTK
SCHEMBL4862072 0.78 ACACB (0.38) CALCAACACB
SCHEMBL5658553 0.77 CALCRL (0.42) CALCAACACBACACACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US claimed
US-7205294-B2 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-17 US disclosed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BDKRB1, BDKRB2, CALCRL RXRA 1259/4885RXRB 834/4885RXRG 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.